Hepatology International

Papers
(The H4-Index of Hepatology International is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
The safety profile of endoscopic variceal ligation in patients with esophageal varices106
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)91
Metabolically healthy obese and MAFLD: does weight status alone matter?88
Platelets in acute liver failure: an innocent bystander or instigator?74
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network69
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial65
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD59
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression58
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure54
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies53
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection50
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis50
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease49
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India46
Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection42
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis41
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria41
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis40
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality39
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”39
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy37
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study35
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma35
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets35
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis34
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study33
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies33
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy32
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes31
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis31
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”30
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation30
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents30
0.16093397140503